Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Higher-dose ocrelizumab versus approved-dose ocrelizumab in relapsing multiple sclerosis
NL-OMON55134Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ocrelizumab in multiple sclerosis (MS) (2 arms), sponsored by Roche. Primary endpoint: Risk reduction in confirmed composite disability progression sustained for at least 12 weeks. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON55134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55134.